Adaptive Biotechnologies/$ADPT
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Adaptive Biotechnologies
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Ticker
$ADPT
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
619
ISIN
US00650F1093
Website
ADPT Metrics
BasicAdvanced
$1.6B
-
-$0.96
1.76
-
Price and volume
Market cap
$1.6B
Beta
1.76
52-week high
$10.87
52-week low
$3.26
Average daily volume
1.3M
Financial strength
Current ratio
2.921
Quick ratio
2.716
Long term debt to equity
109.34
Total debt to equity
115.897
Interest coverage (TTM)
-11.85%
Profitability
EBITDA (TTM)
-117.413
Gross margin (TTM)
53.52%
Net profit margin (TTM)
-74.84%
Operating margin (TTM)
-71.86%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-15.05%
Return on equity (TTM)
-61.03%
Valuation
Price to revenue (TTM)
8.314
Price to book
8.5
Price to tangible book (TTM)
23.64
Price to free cash flow (TTM)
-17.753
Free cash flow yield (TTM)
-5.63%
Free cash flow per share (TTM)
-59.99%
Growth
Revenue change (TTM)
8.61%
Earnings per share change (TTM)
-35.38%
3-year revenue growth (CAGR)
7.04%
3-year earnings per share growth (CAGR)
-16.15%
What the Analysts think about ADPT
Analyst ratings (Buy, Hold, Sell) for Adaptive Biotechnologies stock.
Bulls say / Bears say
Adaptive Biotechnologies' Minimal Residual Disease (MRD) business contributed 81% of revenue in Q3 2024, growing 52% year-over-year, indicating strong demand and potential for continued growth. (ainvest.com)
The company has improved its free cash flow, reporting a positive $194.2 million in 2024, up from -$168.49 million in 2023, reflecting better financial management and operational efficiency. (ainvest.com)
Adaptive Biotechnologies has expanded Medicare coverage for its clonoSEQ test, including Mantle Cell Lymphoma, and obtained an updated Medicare CLFS Gapfill Determination of $2,007 per test, a 17% increase, potentially boosting future revenues. (ainvest.com)
The company's revenue growth has been volatile, with a significant decline of 8.11% in 2023 following a strong increase in 2022, raising concerns about consistent revenue generation. (ainvest.com)
Adaptive Biotechnologies has consistently reported negative operating income over the past five years, with losses ranging from -$145.45 million to -$225.3 million, indicating ongoing profitability challenges. (ainvest.com)
The company's gross margin has been negative, ranging from -2.75% to -40.88%, suggesting operational inefficiencies and potential difficulties in achieving profitability. (ainvest.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
ADPT Financial Performance
Revenues and expenses
ADPT Earnings Performance
Company profitability
ADPT News
AllArticlesVideos
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
GlobeNewsWire·4 weeks ago
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·4 weeks ago
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Adaptive Biotechnologies stock?
Adaptive Biotechnologies (ADPT) has a market cap of $1.6B as of June 25, 2025.
What is the P/E ratio for Adaptive Biotechnologies stock?
The price to earnings (P/E) ratio for Adaptive Biotechnologies (ADPT) stock is 0 as of June 25, 2025.
Does Adaptive Biotechnologies stock pay dividends?
No, Adaptive Biotechnologies (ADPT) stock does not pay dividends to its shareholders as of June 25, 2025.
When is the next Adaptive Biotechnologies dividend payment date?
Adaptive Biotechnologies (ADPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Adaptive Biotechnologies?
Adaptive Biotechnologies (ADPT) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.